Literature DB >> 3216428

Comparison of nerve growth factor's effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro.

J Hartikka1, F Hefti.   

Abstract

In the central nervous system, nerve growth factor (NGF) affects basal forebrain cholinergic neurons during early development and in the adult mammalian brain. These neurons are located in medial septum, diagonal band of Broca, and nucleus basalis of Meynert. While the effects of NGF on the development of septal cholinergic neurons are well documented, only little is known about the influence of NGF on development of cholinergic neurons in the nucleus basalis. In addition to the basal forebrain cholinergic neurons, there are cholinergic interneurons in the corpus striatum, which form an anatomically and functionally distinct population of cholinergic neurons. These striatal interneurons have been reported to respond to NGF during early development; however, it is not known whether the effects of NGF on their development are similar to those on septal cholinergic neurons. We prepared cultures of dissociated cells from fetal rat septum, striatum, and nucleus basalis and investigated the development of cholinergic neurons localized in these three different areas in the presence or absence of NGF. We now report that, first, cholinergic neurons of striatum and nucleus basalis develop a more extensive fiber network and contain more acetylcholinesterase (AChE) per neuron than do cholinergic neurons of septum. The amount of choline acetyltransferase (ChAT) per cholinergic neuron is approximately the same in all three culture types when grown in the absence of NGF. Second, NGF treatment increases and anti-NGF treatment decreases the number of AChE-positive neurons in cultures of low plating density, suggesting that NGF is able to promote survival of cholinergic neurons of all three areas studied. Third, NGF increases the total length of fibers and the number of branching points of cholinergic neurons in septal cultures but not in cultures of striatum and nucleus basalis. Fourth, NGF treatment increases AChE activity in septal but not in nucleus basalis or striatal cultures, suggesting that AChE activity reflects the extent of the fiber network of cholinergic neurons of all areas. Fifth, NGF treatment produces severalfold elevations in ChAT activity in septal cultures and more modest increases in cultures of nucleus basalis and striatum, suggesting that NGF is able to stimulate ChAT activity also in the absence of a stimulatory effect on survival and fiber growth. Our results demonstrate that, during early development, NGF is able to affect survival and differentiation of all three populations of forebrain cholinergic neurons.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3216428     DOI: 10.1002/jnr.490210227

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  16 in total

Review 1.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

2.  Activation of TrkA by nerve growth factor upregulates expression of the cholinergic gene locus but attenuates the response to ciliary neurotrophic growth factor.

Authors:  B Berse; I Lopez-Coviella; J K Blusztajn
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

3.  Effects of nerve growth factor on acetylcholinesterase activity of the proximal stump of the transected sciatic nerve.

Authors:  S Baykal; H Usul; Y Aliyacioğlu; H Efe; S Duru
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

4.  Developmental suppression of forebrain trkA receptors and attentional capacities in aging rats: A longitudinal study.

Authors:  Brittney Yegla; Vinay Parikh
Journal:  Behav Brain Res       Date:  2017-08-10       Impact factor: 3.332

5.  Effect of amyloid peptides on the increase in TrkA receptor expression induced by nicotine in vitro and in vivo.

Authors:  Xinyu D Li; Esperanza Arias; Ramamohana R Jonnala; Shyamala Mruthinti; Jerry J Buccafusco
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

6.  Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy.

Authors:  C Bäckman; G M Rose; B J Hoffer; M A Henry; R T Bartus; P Friden; A C Granholm
Journal:  J Neurosci       Date:  1996-09-01       Impact factor: 6.167

7.  APP is phosphorylated by TrkA and regulates NGF/TrkA signaling.

Authors:  Carmela Matrone; Alessia P M Barbagallo; Luca R La Rosa; Fulvio Florenzano; Maria T Ciotti; Delio Mercanti; Moses V Chao; Pietro Calissano; Luciano D'Adamio
Journal:  J Neurosci       Date:  2011-08-17       Impact factor: 6.167

8.  BMP9 (bone morphogenetic protein 9) induces NGF as an autocrine/paracrine cholinergic trophic factor in developing basal forebrain neurons.

Authors:  Aletta C Schnitzler; Tiffany J Mellott; Ignacio Lopez-Coviella; Yvonne N Tallini; Michael I Kotlikoff; Maximillian T Follettie; Jan Krzysztof Blusztajn
Journal:  J Neurosci       Date:  2010-06-16       Impact factor: 6.167

9.  Diminished trkA receptor signaling reveals cholinergic-attentional vulnerability of aging.

Authors:  Vinay Parikh; William M Howe; Ryan M Welchko; Sean X Naughton; Drew E D'Amore; Daniel H Han; Monika Deo; David L Turner; Martin Sarter
Journal:  Eur J Neurosci       Date:  2012-12-11       Impact factor: 3.386

10.  Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons.

Authors:  Myriam Escobar-Khondiker; Matthias Höllerhage; Marie-Paule Muriel; Pierre Champy; Antoine Bach; Christel Depienne; Gesine Respondek; Elizabeth S Yamada; Annie Lannuzel; Takao Yagi; Etienne C Hirsch; Wolfgang H Oertel; Ralf Jacob; Patrick P Michel; Merle Ruberg; Günter U Höglinger
Journal:  J Neurosci       Date:  2007-07-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.